Ardelyx Inc (ARDX NASDAQ) stock market data APIs
$5.6408
0.17(3%)
as of November 4, 2025
Try our APIs with
free plan!
Ardelyx Inc Financial Data Overview
Price chart is built with
Anychart
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Prev. Close
5.6408
Open
5.8123
High
6.0417
Low
5.6257
52 wk Range
3.21-6.78
Market Cap
1 361 M
Shares Outstanding
243 M
Revenue
398 M
EPS
-0.004
Beta
0.541
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ardelyx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ardelyx Inc data using free add-ons & libraries
Get Ardelyx Inc Fundamental Data
Ardelyx Inc Fundamental data includes:
- Net Revenue: 398 M
- EBITDA: -35 298 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -0.0569
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ardelyx Inc News
New
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago. These figures are adj...
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected t...
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studiesdemonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients...
2 Overlooked Stocks to Snap Up in 2025
While investors chase the usual market darlings, a few underappreciated businesses are quietly gaining traction by generating actual revenue growth, expanding margins, and setting themselves up for lo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
